Last reviewed · How we verify
Behçet's disease affecting oral mucosa
Approved treatments
- Otezla · Amgen
Apremilast inhibits PDE4, increasing intracellular cAMP levels, but the exact therapeutic mechanism is unclear. - Otezla · L.H. Kircik, M.D.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Behçet's disease affecting oral mucosa patent landscape — cliff calendar, originator estates, attackable patents
- Behçet's disease affecting oral mucosa treatment landscape brief
- Behçet's disease affecting oral mucosa treatment updates RSS
Frequently asked questions about Behçet's disease affecting oral mucosa
What drugs treat Behçet's disease affecting oral mucosa?
Tracked treatments include Otezla.
What is the treatment for Behçet's disease affecting oral mucosa?
Standard treatment for Behçet's disease affecting oral mucosa includes Otezla. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Behçet's disease affecting oral mucosa patent cliff · Behçet's disease affecting oral mucosa CI report
- Treatment: Otezla · Amgen
- Treatment: Otezla · L.H. Kircik, M.D.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing